Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Urolithiasis
Published in: Urolithiasis 1/2016

01-02-2016 | Invited Review

Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?

Author: Hans-Göran Tiselius

Published in: Urolithiasis | Issue 1/2016

Login to get access

Abstract

In this review, aspects on the importance of information on urine composition and selection of the most appropriate regimen for prevention of recurrence are discussed. For patients with urolithiasis the treatment is facilitated by urine analysis with estimates of supersaturation levels. Despite lack of strong scientific evidence for the benefit of selective versus non-selective prevention of recurrence in patients with calcium stone disease, there is currently both convincing and logical information in support of tailored/selective treatment regimens aiming at correction of abnormal target variables. Such an approach is also recommended in the EAU and AUA guidelines. It is important, however, that every preventive regimen is balanced between the effects on urine composition and patients’ tolerance to the treatment in order to achieve satisfactory compliance. It is possible that future improved understanding of the causes of calcium stone formation might provide a different therapeutic approach.
Literature
1.
Trinchieri A, Dormia G, Montanari E, Zanetti G (2004) Cystinuria: definition, epidemiology and clinical aspects. Arch Ital Urol Androl 76:129–134PubMed
2.
Ahlstrand C, Tiselius HG (1990) Recurrences during a 10-year follow-up after first renal stone episode. Urol Res 18:397–399CrossRefPubMed
3.
Türk C, Knoll T, Petrik A, Sarica K, Skolarikos M, Straub M, Seitz C (2014) Guidelines on urolithiasis. In: European Association of Urology Guidelines. EAU Guidelines Office, Arnhem, The Netherlands
4.
Leusmann D, Blaschke R, Schmandt W (1990) Result of 5,035 stone analyses: a contributionto epidemiology of urinary stone disease. Scand J Urol Nephrol 24:205–210CrossRefPubMed
5.
Hering F, Lueoend G, Briellmann T, Seiler H, Guggenheim H, Rutishauser G (1988) Stone formation in the human kidney. In: Walker VR, Sutton RL, Cameron B, Pak CYC, Roberston WG (eds) Urolithiasis. Plenum Press, New York, pp 73–74
6.
Tiselius H-G, Alken P, Buck C, Gallucci M, Knoll T, Sarica K, Türk C (2009) Guidelines on urolithiasis. In: European Association of Urology Guidelines. EAU Guidelines Office, Arnhem, The Netherlands
7.
Cloutier J, Villa L, Traxer O, Daudon M (2015) Kidney stone analysis: “Give me your stone, I will tell you who you are!”. World J Urol 33:157–169PubMedCentralCrossRefPubMed
8.
Brand E, Harris MM, Bildon S (1930) Cystinuria: excretion of a cystine complex which decomposes in the urine with liberation of free cystine. J Biol Chem 86:315
9.
Hesse A, Tiselius H, Siener R, Hoppe R (2009) Crystals in the urinary sediment. In: Hesse A, Tiselius HG, Siener R, Hoppe B (eds.) Urinary stones, diagnosis, treatment and prevention of recurrence. Karger AG, Basel, pp 213–215
10.
Fogazzi GB (1996) Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial Transpl 11:379–387CrossRef
11.
Tiselius HG (2002) Medical evaluation of nephrolithiasis. Endocrinol Metab Clin North Am 31:1031–1050CrossRefPubMed
12.
Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, Türk C (2014) Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol S0302–2838:01102–01106
13.
Tiselius HG (1996) Solution chemistry of supersaturation. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management. Lippincott-Raven Publishers, Philadelphia, pp 33–64
14.
Evan AP, Coe FL, Lingeman JE, Shao Y, Sommer AJ, Bledsoe SB, Anderson JC, Worcester EM (2007) Mechanism of formation of human calcium oxalate renal stones on Randall’s plaque. Anat Rec 290:1315–1323CrossRef
15.
Tiselius H (2011) A hypothesis of calcium stone formation: an interpretation of stone research during the past decades. Urol Res 39:231–243CrossRefPubMed
16.
Tiselius HG (2015) Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate? Urolithiasis 43(Suppl 1):47–57CrossRefPubMed
17.
18.
Tiselius HG (2011) A hypothesis of calcium stone formation: an interpretation of stone research during the past decades. Urol Res 39:231–243CrossRefPubMed
19.
20.
Tiselius HG, Bek-Jensen H, Fornander AM, Nilsson MA (1995) Crystallisation properties in urine from calcium oxalate stone formers. J Urol 154:940–946CrossRefPubMed
21.
Heilberg IP, Goldfarb D (2013) Optimum nutrition for kidney stone disease. Adv Chronic Kidney Dis 20:165–174CrossRefPubMed
22.
23.
Fink H, Akornor J, Garimella P, Macdonald R, Cutting A, Rutks I, Monga M, Wilt T (2009) Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. Eur Urol 56:72—80PubMedCentralCrossRefPubMed
24.
Kocvara R, Plasgura P, Petrík A, Louzenský G, Bartonícková K, Dvorácek J (1999) A prospective study of nonmedical prophylaxis after a first kidney stone. BJU Int 84:393–398CrossRefPubMed
25.
Tiselius H-G, Alken P, Buck C, Gallucci M, Knoll T, Sarica K, Türk C (2009) EAU Guidelines on urolithiasis. In: European Association of Urology Guideline. EAU Guidelines Office, Arnhem, The Netherlands
26.
Ahlstrand C, Sandvall K, Tiselius HG (1995) Prophylactic treatment of calcium stone formers with hydrochlorothiazide and magnesium. In: Renal stones-aspects on their formation, removal and prevention. In: Tiselius HG (ed) Proceedings of the Sixth European Symposium on Urolithiasis. Linköping University, pp 195–197
27.
Elomaa I, Ala-Opas MLP (1984) Five years of experience with selective therapy in recurrent calcium nephrolithiasis. J Urol 132:656–661PubMed
28.
Brocks P, Dahl C, Wolf H, Transbøl I (1981) Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet 18:124–125CrossRef
29.
Ettinger B, Tang A, Citron JT, Livermore B, Williams T (1986) Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 27:1386–1389CrossRef
30.
Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Monga M (2013) Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies, Number 61 Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jul. AHRQ Publication No. 12-EHC049-EF
31.
Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD, Clinical Guidelines Committee of the American College of Physicians (2014) Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 16:659–667CrossRef
32.
Pearle MS, Roehrborn CG, Pak CY (1999) Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13:679–685CrossRefPubMed
33.
Robertson WG (2006) Is prevention of stone recurrence financially worthwhile? Urol Res 34:157–161CrossRefPubMed
34.
Yendt ER, Guay GF, Garcia DA (1970) The use of thiazides in the prevention of renal calculi. Can Med Assoc J 102:614–620PubMedCentralPubMed
35.
36.
Ala-Opas M, Elomaa I, Porkka L, Alfthan O (1987) Unprocessed bran and intermittent thiazide therapy in prevention of recurrent urinary calcium stones. Scand J Urol Nephrol 21:311–314CrossRefPubMed
37.
Tiselius HG, Larsson L, Hellgren E (1986) Clinical results of allopurinol treatment in prevention of calcium oxalate stone formation. J Urol 136:5–53
38.
Ahlstrand C, Tiselius HG, Larsson L, Hellgren E (1984) Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers. Br J Urol 56:255–262CrossRefPubMed
39.
Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR, Association AUA (2014) Medical management of kidney stones: AUA guideline. J Urol 192:316–324CrossRefPubMed
40.
41.
Bek-Jensen H, Tiselius HG (1989) Stone formation and urine composition in calcium stone formers without medical treatment. Eur Urol 16:144–150PubMed
42.
Tiselius HG (1999) Factors influencing the course of calcium oxalate stone disease. Eur Urol 36:363–370CrossRefPubMed
43.
Tiselius H-G (1989) Standardized estimate of the ion-activity product of calcium oxalate in urine from renal stone formers. Eur Urol 16:48–50PubMed
44.
Tiselius HG (2005) Aetiological factors in stone formation. In: Davison AM, Cameron JS, Grünfeld J-P, Ritz E, Winearls CG, van Ypersele C (eds) Oxford textbook of clinical nephrology, 3rd edn. Oxford University Press, Oxford, pp 1199–1223
45.
Ahlstrand C, Tiselius HG (1987) Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 21:225–228CrossRefPubMed
46.
Muldowney FP, Freaney R, Moloney MF (1982) Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 22:292–296CrossRefPubMed
47.
Metadata
Title
Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?
Author
Hans-Göran Tiselius
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
Urolithiasis / Issue 1/2016
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-015-0840-y

Other articles of this Issue 1/2016

Urolithiasis 1/2016 Go to the issue

Invited Review

Dietary recommendations and treatment of patients with recurrent idiopathic calcium stone disease

Invited Review

Preface

Invited Review

Treatment of patients with uric acid stones

Invited Review

Lowering urinary oxalate excretion to decrease calcium oxalate stone disease

Invited Review

Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

Invited Review

How should patients with cystine stone disease be evaluated and treated in the twenty-first century?